Astrana Health (NASDAQ:ASTH) Issues Earnings Results, Misses Estimates By $0.14 EPS

Astrana Health (NASDAQ:ASTH - Get Free Report) issued its earnings results on Thursday. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.28 by ($0.14), Zacks reports. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. Astrana Health's revenue for the quarter was up 53.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.31 earnings per share. Astrana Health updated its Q2 2025 guidance to EPS and its FY 2025 guidance to EPS.

Astrana Health Stock Down 11.3 %

ASTH stock traded down $3.77 during midday trading on Friday, reaching $29.67. 387,408 shares of the company's stock traded hands, compared to its average volume of 281,755. Astrana Health has a 52 week low of $23.12 and a 52 week high of $63.20. The company has a market cap of $1.66 billion, a price-to-earnings ratio of 22.82, a P/E/G ratio of 1.37 and a beta of 1.00. The firm's fifty day moving average price is $30.90 and its 200-day moving average price is $36.40. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ASTH shares. Truist Financial cut their price objective on Astrana Health from $50.00 to $46.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th. Stifel Nicolaus reduced their price target on Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Barclays started coverage on shares of Astrana Health in a report on Tuesday, April 1st. They issued an "equal weight" rating and a $36.00 price objective for the company. Bank of America reduced their target price on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Finally, Robert W. Baird reduced their price objective on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $53.29.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.